Abstract
Purpose
Although overall there is a positive association between obesity and risk of prostate cancer (PrCa) recurrence, results of individual studies are somewhat inconsistent. We investigated whether the failure to exclude diabetics in prior studies could have increased the likelihood of conflicting results.
Methods
A total of 610 PrCa patients who underwent radical prostatectomy between 2005 and 2012 were followed for recurrence, defined as a rise in serum PSA ≥ 0.2 ng/ml following surgery. Body mass index (BMI) and history of type 2 diabetes were documented prior to PrCa surgery. The analysis was conducted using Cox proportional hazard models.
Results
Obesity (25.6 %) and diabetes (18.7 %) were common in this cohort. There were 87 (14.3 %) recurrence events during a median follow-up of 30.8 months after surgery among the 610 patients. When analyzed among all PrCa patients, no association was observed between BMI/obesity and PrCa recurrence. However, when analysis was limited to non-diabetics, obese men had a 2.27-fold increased risk (95 % CI 1.17–4.41) of PrCa recurrence relative to normal weight men, after adjusting for age and clinical/pathological tumor characteristics.
Conclusions
This study found a greater than twofold association between obesity/BMI and PrCa recurrence in non-diabetics. We anticipated these results because the relationship between BMI/obesity and the biologic factors that may underlie the PrCa recurrence–BMI/obesity association, such as insulin, may be altered by the use of anti-diabetes medication or diminished beta-cell insulin production in advanced diabetes. Studies to further assess the molecular factors that explain the BMI/obesity–PrCa recurrence relationship are warranted.
Similar content being viewed by others
References
American Cancer Society (ACS) (2014) Cancer facts & figures 2014. Atlanta, GA
Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S et al (2014) SEER cancer statistics review, 1975–2011. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2011/. Based on November 2013 SEER data submission, posted to the SEER web site, April 2014
Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et al (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78–85
Carter HB, Piantadosi S, Isaacs JT (1990) Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 143(4):742–746
MacInnis RJ, English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17(8):989–1003
Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW et al (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev 15(10):1977–1983
Hsing AW, Sakoda LC, Chua S Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86(3):s843–s857
Freedland SJ, Platz EA (2007) Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29:88–97
Cao Y, Ma J (2011) Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res 4(4):486–501
Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Feng Z, Trock BJ et al (2014) Obesity and long-term survival after radical prostatectomy. J Urol 192(4):1100–4. doi:10.1016/j.juro.2014.04.086
Hu MB, Xu H, Bai PD, Jiang HW, Ding Q (2014) Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose–response meta-analysis of 36,927 patients. Med Oncol 31(2):829
Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915–928
Renehan AG, Frystyk J, Flyvbjerg A (2006) Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17(8):328–336
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J et al (2008) A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomark Prev 17:921–929
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE et al (2009) Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101(1):48–60
Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomark Prev 15(11):2056–2062
Zhang F, Yang Y, Skrip L, Hu D, Wang Y, Wong C et al (2012) Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetol 49(Suppl 1):S235–S246
Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35(2):299–304
Oh JJ, Hong SK, Lee S, Sohn SJ, Lee SE (2013) Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy. Int Urol Nephrol 45(1):121–127
Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI et al (2014) Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol 32(4):999–1005. doi:10.1007/s00345-013-1171-7
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364–1379
American Diabetes Association (2014) Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl 1):S14–S80
Ligibel JA, Strickler HD (2013) Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions. Am Soc Clin Oncol Educ Book. 2013:52-9. doi:10.1200/EdBook_AM.2013.33.52
Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc B 34:187–220
Hosmer DW, Lemeshow S (1999) Applied survival analysis. Wiley, New York
Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303(3):235–241
Ogden CL, Carrol MD, Kit BK, Flegal KM (2012) Prevalence of obesity in the United States, 2009–2010. In: National Center for Health Statistics (NCHS) Data Brief 2012, vol 82, pp 1–7
Wong RJ, Chou C, Ahmed A (2014) Long Term Trends and Racial/Ethnic Disparities in the Prevalence of Obesity. J Community Health 39(6):1150–1160
Asmar R, Beebe-Dimmer JL, Korgavkar K, Keele GR, Cooney KA (2013) Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 16(1):62–66
Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ et al (2005) Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 66(5):1060–1065
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–1047
Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K, Virtamo J (2009) Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 101(18):1272–1279
Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M (2009) Insulin receptor expression by human prostate cancers. Prostate 69(1):33–40
de Visser KE, Coussens LM (2006) The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 13:118–137
Gerber PA, Hippe A, Buhren BA, Muller A, Homey B (2009) Chemokines in tumor-associated angiogenesis. Biol Chem 390(12):1213–1223
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899
Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16(1):38–52
de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24–37
Rosenkilde MM, Schwartz TW (2004) The chemokine system—a major regulator of angiogenesis in health and disease. Apmis 112(7–8):481–495
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7(4):256–269
Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172(5 Pt 2):S6–S11 discussion S11–12
Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E (2000) Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 37(4):404–412
Klink JC, Banez LL, Gerber L, Lark A, Vollmer RT, Freedland SJ (2013) Intratumoral inflammation is associated with more aggressive prostate cancer. World J Urol 31(6):1497–1503
Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncoso P (2005) Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11(19 Pt 1):6889–6894
Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EB, Freedland SJ, Walsh PC, Platz EA (2011) Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res 4(4):544–551
Diabetes Prevention Program Research Group (2012) Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care 35(4):731–737
Malin SK, Kashyap SR (2014) Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes 21(5):323–329
Acknowledgments
Dr. Ilir Agalliu was supported by a Mentored Research Scholar Grant (MRSG-11-112-01-CNE) from the American Cancer Society.
Author information
Authors and Affiliations
Corresponding author
Additional information
Howard D. Strickler and Reza Ghavamian have contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Agalliu, I., Williams, S., Adler, B. et al. The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics. Cancer Causes Control 26, 821–830 (2015). https://doi.org/10.1007/s10552-015-0554-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-015-0554-z